Claudia Zelle-Rieser

Claudia Zelle-Rieser

Auto-generated profile, based on publicly available information

Claudia Zelle-Rieser

Department of Dermatology, Venereology & Allergology, Medical University Innsbruck, Innsbruck, Austria

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2001 in Immunology Letters
Verified
Journal Article
Closed access
CZClaudia Zelle-Rieser
Claudia Zelle-Rieser
RRReinhold Ramoner
Reinhold Ramoner
GBGeorg Bartsch
Georg Bartsch
Martin ThurnherMartin Thurnher
Martin Thurnher

1 January 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
LBLydia Bellmann
Lydia Bellmann
CZClaudia Zelle-Rieser
Claudia Zelle-Rieser
PMPaul Milne
Paul Milne
ARAnastasia Resteu
Anastasia Resteu
CTChristoph Heinrich Tripp
Christoph Heinrich Tripp
PSPatrizia Stoitzner
Patrizia Stoitzner
Langerhans cells (LCs) in the skin are a first line of defense against pathogens but also play an essential role in skin homeostasis. Their exclusive expression of the C-type lectin receptor Langerin makes them prominent candidates for immunotherapy. For vaccine testing, an easily accessible cell platform would be desirable as an alternative to the time-consuming purification of LCs from human skin. Here, we present such a model and demonstrate that monocytes in the presence of GM-CSF, TGF-β1, and the Notch ligand DLL4 differentiate within 3 days into CD1a+Langerin+cells containing Birbeck granules. RNA sequencing of these monocyte-derived LCs (moLCs) confirmed gene expression of LC-related molecules, pattern recognition receptors, and enhanced expression of genes involved in the antigen-presenting machinery. On the protein level, moLCs showed low expression of costimulatory molecules but prominent expression of C-type lectin receptors. MoLCs can be matured, secrete IL-12p70 and TNF-α, and stimulate proliferation and cytokine production in allogeneic CD4+ and CD8+ T cells. In regard to vaccine testing, a recently characterized glycomimetic Langerin ligand conjugated to liposomes demonstrated specific and fast internalization into moLCs. Hence, these short-term in vitro‒generated moLCs represent an interesting tool to screen LC-based vaccines in the future.

9 January 2022 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
LBLydia Bellmann
Lydia Bellmann
HSHelen Strandt
Helen Strandt
CZClaudia Zelle‐Rieser
Claudia Zelle‐Rieser
DODaniela Ortner-Tobider
Daniela Ortner-Tobider
CTChristoph Heinrich Tripp
Christoph Heinrich Tripp
PSPatrizia Stoitzner
Patrizia Stoitzner
Human skin is a preferred vaccination site as it harbors multiple dendritic cell (DC) subsets, which display distinct C‐type lectin receptors (CLR) that recognize pathogens. Antigens can be delivered to CLR by antibodies or ligands to boost antigen‐specific immune responses. This concept has been established in mouse models but detailed insights into the functional consequences of antigen delivery to human skin DC in situ are sparse. In this study, we cloned and produced an anti‐human Langerin antibody conjugated to the EBV nuclear antigen 1 (EBNA1). We confirmed specific binding of anti‐Langerin‐EBNA1 to Langerhans cells (LC). This novel LC‐based vaccine was then compared to an existing anti‐DEC‐205‐EBNA1 fusion protein by loading LC in epidermal cell suspensions before coculturing them with autologous T cells. After restimulation with EBNA1‐peptides, we detected elevated levels of IFN‐γ‐ and TNF‐α‐positive CD4+ T cells with both vaccines. When we injected the fusion proteins intradermally into human skin explants, emigrated skin DC targeted via DEC‐205‐induced cytokine production by T cells, whereas the Langerin‐based vaccine failed to do so. In summary, we demonstrate that antibody‐targeting approaches via the skin are promising vaccination strategies, however, further optimizations of vaccines are required to induce potent immune responses.

15 February 2012 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
KJKarin Jöhrer
Karin Jöhrer
SHSebastian W Hofbauer
Sebastian W Hofbauer
CZClaudia Zelle-Rieser
Claudia Zelle-Rieser
RGRichard Greil
Richard Greil
Tanja HartmannTanja Hartmann
Tanja Hartmann
Introduction: Chemokines and their receptors play essential roles in the development, maintenance and proper functioning of the immune system. B cell–T cell interactions are modulated by chemokines. In B cell malignancies, these interactions may have tumor-promoting consequences. Areas covered: This review summarizes physiological B cell–T cell interactions and discusses their pathological role in the onset and progression of B cell malignancies with a special focus on chronic lymphocytic leukemia and multiple myeloma. Experimental data on chemokine-guided B cell-T cell actions in B cell malignancies from murine models as well as in vitro data are summarized and their potential as future therapeutic targets is critically discussed. Expert opinion: Direct or indirect targeting of chemokine receptors involved in localization and T-cell-dependent activation of B lymphocytes can provide strong synergisms with conventional or immunomodulatory therapies by disrupting the microenvironmental conditions necessary for survival and proliferation of malignant B lymphocytes. However, further knowledge of these interactions between B and T cells is needed.

7 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SVSimon Christian Vinther
Simon Christian Vinther
ARAntonia Resag
Antonia Resag
KLKarina Thao Thu Le
Karina Thao Thu Le
CZClaudia Christine Zelle-Rieser
Claudia Christine Zelle-Rieser
HSHelen Strandt
Helen Strandt
JKJørgen Kjems
Jørgen Kjems
The skin is a diverse reservoir of immune cells with strong potential for immunotherapeutic delivery. Langerhans cells (LCs) in the epidermis are antigen-presenting cells, accessible for vaccination using carbohydrate-conjugated therapeutics targeting their endocytic lectin receptor, Langerin. As carbohydrate-lectin binding is highly dependent on valency, scaffolds that enable control over ligand spacing and stoichiometry are instrumental in enhancing receptor binding and selectivity. Here we utilized a self-assembled nucleic acid-based Holliday Junction scaffold, fully modified for nuclease protection and with a well-defined carbohydrate arrangement to optimize drug delivery to LCs. In vitro screening with Langerin-expressing cells revealed that mannosylated Holliday Junctions showed the strongest binding. This was confirmed in human epidermal cell suspensions, demonstrating specificity and valency-driven interactions. Topical administration of mannosylated scaffolds on skin explants enabled effective targeting of epidermal LCs. Finally, in an antigen-presentation assay, in vitro differentiated LCs loaded with mannosylated and peptide-conjugated scaffolds significantly enhanced T cell activation. Overall, our study presents a promising nucleic acid-based platform for precise LC targeting and drug delivery, with broad potential for skin-directed immunotherapies.

17 April 2026 in Prävention und Gesundheitsförderung
Verified
Journal Article
Closed access
CZClaudia Zelle-Rieser
Claudia Zelle-Rieser
SDSimone Davidsen
Simone Davidsen
GBGilles Bernard
Gilles Bernard
KMKurt Martini
Kurt Martini
DFDemian Frank
Demian Frank
EJEva Maria Jabinger
Eva Maria Jabinger